fashion -WSS

fashion

author：explore 2025-10-01 21:47:52 - browse：1

Dozens of sickle cells in a whirlpool — coverage from STAT — Adobe

Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes.

The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Pediatric cancer treatments threatened by a new FDA policy

Wikipedia

WSS

Pediatric cancer treatments threatened by a new FDA policy

Elizabeth Holmes on track for early release from her 11

Disappointing trial forces Pfizer to pivot on obesity medicine plans

What don’t we know about an Alzheimer’s drug side effect?

A new study sees potential in DNA sequencing of infants

Petition to FDA: Get the lead out of consumer hair dyes

leisure time

fashion

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Study: Pain burden is higher in Black NFL players than white ones

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Despite FDA concern, risk that CAR

Supreme Court strikes down use of affirmative action

U.K. Biobank has 500,000 peoples' genome sequences available

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Psychedelics group wrestles with new pharma identity

Lecanemab for Alzheimer's is coming. Is the health system ready?

entertainment

What to do when lifesaving products contribute to climate change

Diagnostic tests are hitting their mathematical limits

How the political right came to back psychedelics to treat trauma

BIO selects John Crowley as new CEO

FDA investigates CAR

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Wikipedia

explore

explore

focus